Iantech

United States
Homeland, California, United States

Company profile

Iantech company profile

Iantech has developed advanced micro-­interventional technology for cataract surgery. After 50 years of conventional phacoemulsification, Iantech introduces a micro-­interventional technique designed to deliver energy-­free endocapsular lens fragmentation, giving surgeons control, efficiency and new opportunities to improve their surgical technique. At Iantech, They are working to invent new surgical approaches which can reduce the global footprint of cataract blindness. Using smart, efficient and adaptable micro-­interventional technology, Their team is building a new surgical platform to catalyze global outreach efforts as we fight the 25M blindness epidemic in the world

Business identity

Contact email
[email protected]
Operating status
Closed
Company type
For Profit
Employee range
1-10 employees
Revenue range
$0-$1M
Founded
2013-01-01, Year

Headquarters

Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
M And A
Funding rounds
2
Total equity funding
$8.2M
Last funding
Series C / $4.5M / 2017-07-13
Last equity funding
Series C / $4.5M
Investors
2
Lead investors
2
Founders
1
Articles
1
Exited on
2018-10-23

Founders and investors

Founders

Luke Clauson

Lead investors

Global Health Investment Fund (GHIF)Visionary Venture Fund

Investors

Global Health Investment Fund (GHIF)Visionary Venture Fund